The study of GEN-001 with Avelumab for PD-L1 Positive Gastric Cancer

Genome & Company is recruiting patients for the clinical trial of GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer.

This is a phase II, multicenter, open-label study to evaluate the antitumor activity, efficacy and safety of GEN-001 in combination with avelumab as a third line (3L) or greater line treatment which is not received the Standard of Care (SOC) for patients with PD-L1 positive advanced GC/Gastroesophageal Junction Adenocarcinoma who are not received cancer immunotherapy regimens as mono or combination therapy.

The study commenced on April 7, 2022, with the indicative completion in September 2024.

Among primary outcome measures are the to assess the anti-tumor activity of GEN-001, when administered as combined with avelumab and Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

The page dedicated to this clinical trial can be found here: or

Clinical Research News

Upcoming Clinical Trials